CSPC Pharmaceutical and Pfizer to Launch Local Brand of Paxlovid in China
Chinese drugmaker CSPC Pharmaceutical announced on Jun. 28, 2023, that it has signed a strategic partnership agreement with Pfizer to launch a local brand of the Covid-19 oral therapeutic treatment Paxlovid in China. The goal is to improve access to this treatment in China.
Paxlovid, a combination of Nirmatrelvir and Ritonavir, is an oral small molecule used to treat patients with mild to moderate Covid-19 symptoms who are at risk of disease progression such as the elderly (patients over 60) or patients with one or more risk factors, such as chronic kidney disease, diabetes, cardiovascular disease or chronic lung disease.
In May of this year, Pfizer's oral anti-viral Covid-19 treatment had won full approval from the US Food and Drug Administration (FDA) after Emergency Use Authorization was granted in late 2021.
Through this partnership with Pfizer, Shijiazhuang-based CSPC Pharmaceutical said that it can share the synergistic effects of the strengths of both parties, which can help improve the accessibility of Covid-19 antiviral drugs in China and reduce the risk of severe illness and death, thus contributing to the prevention and control of the pandemic in China.
